Viaskin is a dry, disc-shaped cutaneous device system that holds an active ingredient in powder form on an electrically charged plastic film that only delivers it when Viaskin is placed on the skin
DBV Technologies has developed a unique technology, Viaskin, for the cutaneous administration of proteins and peptides.
The company released the first ready-to-use patch test for diagnosing cow's milk allergy based on this unique technology: Diallertest Milk.
DVB Technologies will exhibit at Bio 2007 in Boston 6-9 May 2007, and will present Viaskin and its applications at the Bio Business Forum on 8 May at 9:15am.
Application of the disc creates a occlusive chamber between the disc and the skin, making the chamber's conditions humid enough to hydrate and release the active ingredient, and to open the skin's pores to better absorb the active ingredient.
Diallertest Milk uses this technology to diagnose cow's milk protein allergy and is suitable for everyday medical practice.
Practical, simple to use, and painless as it is completely non-invasive, and it can be applied directly by the parents to the child's back at home.
It significantly improves the effectiveness in the diagnosis of cow's milk protein allergy.
The faster the diagnosis and treatment, the lower the risk of developing allergosis.
DVB is also developing Diallertest to diagnose dust mite, soy, and wheat allergies.
The milk allergy test will soon be available to the United States.
DBV Technologies and Numico, a Dutch company specialising in the production and sale of nutritional foodstuffs, have announced a distribution agreement for Diallertest Milk that will extend its original network to include the entire world.
Since February 2006, Nutricia, Numico's French subsidiary, has distributed Diallertest Milk in France.
Today, about 70,000 tests have already been prescribed.
The test is available in Australia, France, the Middle East, and New Zealand.
Founded in 2002, DBV Technologies was created by Pierre-Henri Benhamou, a pediatrician specialising in gastro-enterology, allergosis, and nutrition, and Bertrand Dupont, a qualified engineer from the Arts et Metiers institute.
Today it is chaired by Jean-Francois Biry, CEO.
The company has perfected and globally patented the Viaskin technology.
Viaskin is a unique delivery system that retains the active principle on the carrier using electrostatic forces only.
One of the initial applications of this patch is the diagnosis and treatment of allergies.
